Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02523014
Title Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors Alliance for Clinical Trials in Oncology
Indications

meningioma

Therapies

Abemaciclib

GSK2256098

Vismodegib

Capivasertib

Age Groups: adult | senior
Covered Countries USA

Additional content available in CKB BOOST